VYNE Therapeutics Inc.
For every therapeutic challenge, we question traditional assumptions and find better solutions.
For every therapeutic challenge, we question traditional assumptions and find better solutions.
VYNE Therapeutics Inc. is a United States-based company founded in 2003. The company's slogan, "For every therapeutic challenge, we question traditional assumptions and find better solutions," reflects its commitment to innovation. VYNE Therapeutics focuses on the development of proprietary, innovative, and differentiated therapies for immuno-inflammatory conditions within the Health Care and Pharmaceutical industries. Its latest milestone includes a significant $88.00M Post-IPO Equity investment on 30 October 2023 from notable investors such as Access Biotechnology, Acorn Bioventures, Cormorant Asset Management, Soleus Capital, Parkman Healthcare Partners LLC, Eventide Asset Management, Palo Alto Investors, and Surveyor Capital. VYNE's mission to improve patients' lives through innovative therapies demonstrates its potential for growth and impact in the healthcare and pharmaceutical sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $88.00M | 8 |
|
30 Oct 2023 |
| Post-IPO Equity | $50.00M | - | 26 Jan 2021 | |
| Post-IPO Equity | $50.04M | - | 05 Jun 2020 | |
| Series C | $50.50M | 9 |
|
18 Jul 2017 |
| Series B | $45.00M | 4 |
|
01 Nov 2015 |
No recent news or press coverage available for VYNE Therapeutics Inc..
We care about your data, and we'd love to use cookies make your experience better.
